在作出所有合理查询后，按董事所知、所悉及所信，Outwit Investments 为一间于英属处女群岛注册成 立的有限责任公司，在完成股份转让前持有本公司 47.09% 的股权。 Outwit Investments 由远大(香港)国 际投资控股有限公司 (远大投资)持有99.85%股本权益。远大投资由中国远大集团有限责任公司 (中国远 大) 全资拥有，而中国远大由北京远大华创投资集团有限公司(北京远大华创)拥有93%权益。 东海资本为一间于香港注册成立的有限责任公司，是上海远大产融投资管理有限公司(上海产融)的全资 附属公司，而北京远大华创持有上海产融的70%股本权益。 北京远大华创由胡凯军先生(胡先生)控制及最终实益拥有。 智通财经APP讯，远大医药(00512)发布公告，董事会接获本公司控股股东 Outwit Investments Limited(Outwit Investments)通知，由于控股股东集团对本公司股权进行内部重组，Outwit Investments 于 2025年7月28日与本公司股东东海资本(香港)有限公司 (东海资本)订立股份转让协议，东海资本同意出 售而 Outwit In ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) （股份代號: 00512） 自願性公告 董事會接獲本公司控股股東 Outwit Investments Limited（「Outwit Investments」）通知， 由於控股股東集團（定義見下）對本公司股權進行內部重組，Outwit Investments 於二零 二五年七月二十八日與本公司股東東海資本(香港)有限公司 （「東海資本」）訂立股份 轉讓協議，據此，東海資本同意出售而 Outwit Investments 同意收購本公司合共 224,373,091 股每股面值 0.01 港元之普通股（「股份」）（「股份轉讓」）。股份轉讓 之交割將於所有先決條件獲得滿足或被豁免以後的六十個營業日內進行。 緊隨上述股份轉讓完成後，Outwit Investments 將合共持有 1 ...

Group 1 - Nanshan Aluminum International (02610.HK) expects a mid-term net profit of approximately $225 million to $265 million for the six months ending June 30, 2025, compared to a net profit of about $159 million for the same period ending June 30, 2024 [1] - The increase in net profit is primarily attributed to an improvement in gross margin, driven by higher alumina prices and relatively stable unit production costs [1] - The average selling price of the company's products for the first half of 2025 is expected to be around $530 per ton, up from approximately $387 per ton in the first half of 2024, but lower than $561 per ton in the second half of 2024 [1] Group 2 - TCL Electronics (01070.HK) anticipates a year-on-year adjusted net profit growth of approximately 45% to 65% for the first half of 2025 [2] - Renrui Talent (06919.HK) expects a mid-term profit attributable to equity holders to increase by 66.7% to 94.1% [2] - China Rare Earth Holdings (03788.HK) reports an increase in total gold resources to 5.07 million ounces [2]

Core Viewpoint - The company, Yuan Da Pharmaceutical, has made significant advancements in its nuclear medicine sector, particularly with the innovative radiopharmaceutical TLX591 for prostate cancer treatment, which has received regulatory approval for international clinical trials, indicating strong potential for market growth and patient benefit [1][2][4]. Group 1: Product Development and Clinical Trials - TLX591, a radiolabeled monoclonal antibody, targets PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) and has shown significant advantages in treatment duration and radiation exposure compared to traditional therapies [2][3]. - The international multi-center Phase III clinical trial for TLX591 aims to enroll over 500 patients across multiple countries, including China, the US, Australia, New Zealand, and Europe, to evaluate its efficacy and safety [1][2]. - TLX591's companion diagnostic product, TLX591-CDx, has already been launched in several countries and is projected to achieve global sales of AUD 783 million in 2024, highlighting its commercial potential [3]. Group 2: Market Potential and Growth - The prostate cancer drug market is expected to grow at a compound annual growth rate (CAGR) of 8.3% to reach USD 37.6 billion by 2030, with China's market projected to grow at a CAGR of 21.8% to reach CNY 50.6 billion [4][5]. - The global prostate cancer diagnostics market is anticipated to exceed USD 11.5 billion by 2032, driven by increasing incidence rates [5]. - The success of Novartis' Pluvicto, which is expected to generate nearly USD 1.4 billion in revenue in 2024, reflects the industry's recognition of the significant market potential in nuclear medicine [5]. Group 3: Company Position and Innovations - Yuan Da Pharmaceutical has a robust pipeline with 15 innovative products in the nuclear medicine oncology sector, covering various cancers and including both diagnostic and therapeutic radiopharmaceuticals [6][9]. - The company has established itself as a leader in the nuclear medicine field, being one of the few globally to commercialize nuclear medicine products successfully [9]. - The newly operational nuclear medicine research and production base in Chengdu, which received a Class A radiation safety license, is set to enhance the company's capabilities in research, production, and sales across the entire nuclear medicine value chain [11][13].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 加入國際多中心 III 期臨床試驗的申請已獲中國藥監局默示許可 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之董事 會(「董事會」)自願刊發。 董事會欣然公告，本集團用於治療前列腺癌的全球創新在研放射性核素偶聯藥物 「( RDC」) TLX591 (177Lu-rosopatamab tetraxetan)加入國際多中心 III 期臨床試驗的申請， 近日已獲得中華人民共和國國家藥品監督管理局(「中國藥監局」)默示許可，這是本集 團在核藥抗腫瘤診療領域的重要研發進展。本集團高度重視核藥產業全球化發展戰略， 積極推進創新核藥產品的全球化開發及註冊進程，並將持續深化本集團核藥產品管線的 全球化拓展。 該研究是一項前瞻性、隨機、對照、開放標籤、國際多中心的 III 期臨床試驗，擬在中 國、美國、澳大利亞、新西蘭及歐洲等全球多個國家和地區入組 500 余名患者，旨在評 估 TLX591 ...

Group 1 - Company recently announced the commercialization of OC-01, a nasal spray product for increasing tear secretion in dry eye patients, marking it as the only approved product of its kind in China [1] - Dry eye disease is a common chronic ocular surface condition in China, with an estimated prevalence of 21%-30%, affecting approximately 360 million people [1] - The innovative nasal delivery method of OC-01 significantly improves natural tear secretion and is expected to enhance patient compliance due to its ease of use compared to traditional eye drops [1] Group 2 - Company has established a strategic focus on the ophthalmology field, developing a comprehensive portfolio of innovative drugs for various eye conditions, with multiple products expected to be approved in the next three years [2] - Recent FDA approval for DOORwaY90, a yttrium-90 microsphere injection, allows it to treat unresectable hepatocellular carcinoma (HCC) without size restrictions, making it the first product to receive such dual indications [2] - The international multi-center Phase III clinical trial for CBT-001, an innovative drug for treating pterygium, has successfully completed patient enrollment [2] Group 3 - On July 17, the company's stock rose by 5.13%, closing at HKD 9.83 per share, with a cumulative increase of over 64% from May 1 to July 17 [3]

Group 1 - Tigermed announced the sale of its stake in Lixin Pharmaceutical, holding a direct stake of 3.41% and an indirect stake of 4.58% through fund holdings, with the total transaction valued at approximately $34.11 million [1] - The sale reflects Tigermed's ability to achieve investment returns and demonstrates its professional post-investment management capabilities as a leading CRO [1] Group 2 - Yuan Da Pharmaceutical's innovative nasal spray product for dry eye treatment, OC-01, has received approval from the National Medical Products Administration and its first commercial prescriptions have been implemented [2] - The product's launch enhances Yuan Da's ophthalmology pipeline and signifies its strategic shift from a traditional pharmaceutical company to an innovative one, with future market performance being promising [2] Group 3 - China Pharmaceutical's general manager, Hu Huidong, has resigned due to work adjustments, which may lead to new development strategies if a new management team with rich industry experience is appointed [3] - The impact of this leadership change should be evaluated in conjunction with the company's fundamentals and subsequent announcements [3] Group 4 - Microchip Biotech expects a significant increase in net profit by 173% for the first half of 2025, with revenue projected at 407.29 million yuan, a 35% year-on-year increase [4] - The company is entering a harvest phase due to its independent R&D capabilities, validating its "small but beautiful" commercialization path, although it must continue to advance its pipeline and manage potential policy risks for sustained growth [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號: 00512) 補充公告 持續關連交易 商業合作協議 茲提述遠大醫藥集團有限公司（「本公司」）於2025年4月25日就商業合作協議項下擬進 行的持續關連交易刊發的公告（「該公告」）。除非另有定義，本公告中使用的詞彙與該 公告中的詞彙具有相同意義。 本公司謹就商業合作協議下擬進行的持續關連交易提供以下補充資料。 研發項目詳情 基於本集團與 Sirtex Group之間良好的合作關係，雙方均認可彼此在製藥業的優勢和 專業知識。雙方共同致力於創新，並尋求在開發不透射線產品方面探索潛在的合作機 會。因此，本集團與 Sirtex Group 簽署了《商業合作協議》，以促進雙方在醫藥產品研 發方面的合作。此類研發合作將涉及共享勞動力和實驗室、採購原材料和耗材、在必 要時採購研究 ...

Group 1: Company Developments - The company has received FDA approval for its innovative drug SIR-Spheres® for treating unresectable hepatocellular carcinoma (HCC) [1] - The company’s nasal spray product OC-01 for dry eye syndrome has been approved in mainland China and has begun commercial prescriptions [1][3] - OC-01 is the only nasal spray approved for treating dry eye syndrome in China, providing a new treatment option for patients [1] Group 2: Market Insights - The dry eye syndrome market in China is estimated to have around 360 million patients, with a prevalence rate of approximately 21.0% to 52.4% [3] - The overall dry eye syndrome market in China has a compound annual growth rate (CAGR) of 1.6% from 2017 to 2021, with moderate growth expected in the coming years [4] - The global dry eye syndrome market is projected to reach $25.48 billion in 2024, expanding at a CAGR of 3.4% to $33.26 billion by 2033 [6] Group 3: Product Advantages - OC-01 utilizes a nasal delivery method that enhances tear secretion and improves tear film stability, potentially increasing patient compliance compared to traditional eye drops [7] - The product has shown strong commercial potential, with over 97,000 prescriptions in the U.S. within its first year and approximately $42 million in sales revenue in 2023 [7] - The company has a comprehensive pipeline of innovative ophthalmic products, including treatments for various eye conditions, which are expected to contribute to future revenue growth [11][14] Group 4: Competitive Landscape - The ophthalmic drug market in China has grown from 15.1 billion RMB in 2016 to 18.8 billion RMB in 2020, with a projected market size of 44 billion RMB by 2025 [8] - The company is strategically positioned in the competitive ophthalmic market, focusing on innovative product development to maintain its leading position [10] - The company has established a professional marketing team and a nationwide distribution network to support its ophthalmic product sales [14]

Group 1 - The company has launched OC-01, a nasal spray for increasing tear secretion in dry eye patients, marking a significant milestone in the treatment of dry eye syndrome in China [1] - OC-01 is the first and only nasal spray approved for treating dry eye symptoms globally, having received approval in the US in October 2021 and in mainland China in November 2024 [1] - The product is expected to provide a new treatment option for dry eye patients in China, enhancing the company's position in the ophthalmic market [1] Group 2 - The company focuses on ophthalmology as a key strategic development direction, emphasizing innovation in ophthalmic drugs and enhancing market competitiveness [2] - A comprehensive product system has been established, with multiple innovative products targeting conditions such as myopia, dry eye syndrome, and post-operative inflammation [2] - The company is committed to advancing innovative products and technologies, aiming to meet unmet clinical needs and expand its product pipeline through a global operational strategy [2]